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Neurofibromatosis type 1 (NF1) is characterized by cafe´-au-lait spots, skinfold freckling, and cutaneous neurofibromas.
No obvious relationships between small mutations (!20 bp) of the NF1 gene and a specific phenotype have previously
been demonstrated, which suggests that interaction with either unlinked modifying genes and/or the normal NF1 allele
may be involved in the development of the particular clinical features associated with NF1. We identified 21 unrelated
probands with NF1 (14 familial and 7 sporadic cases) who were all found to have the same c.2970-2972 delAAT (p.990delM)
mutation but no cutaneous neurofibromas or clinically obvious plexiform neurofibromas. Molecular analysis identified
the same 3-bp inframe deletion (c.2970-2972 delAAT) in exon 17 of the NF1 gene in all affected subjects. The DAAT
mutation is predicted to result in the loss of one of two adjacent methionines (codon 991 or 992) (DMet991), in con-
junction with silent ACArACG change of codon 990. These two methionine residues are located in a highly conserved
region of neurofibromin and are expected, therefore, to have a functional role in the protein. Our data represent results
from the first study to correlate a specific small mutation of the NF1 gene to the expression of a particular clinical
phenotype. The biological mechanism that relates this specific mutation to the suppression of cutaneous neurofibroma
development is unknown.
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Neurofibromatosis type 1 (NF1 [MIM 162200]) is a com-
plex disorder that affects many cell types and involves
multiple body systems. Inheritance is autosomal domi-
nant, with a prevalence of 1 in 4,0001 and with penetrance
of the mutant gene essentially complete by age 5 years.
This inherited disorder is due to germline mutations of
the NF1 gene, a 17q11.2-located gene that spans 280 kb,
is composed of 61 exons, and encodes a 12-kb mRNA
transcript.2,3 Neurofibromin, the NF1 gene product, is a
ubiquitously expressed protein that is usually present at
low levels in essentially all tissues. This large protein
(2,818 aa) exhibits structural and sequence similarity to
the mammalian guanine triphosphatase–activating pro-
tein (GAP)–related protein family, whose members are
evolutionarily conserved. The most highly conserved re-
gion of the protein is the neurofibromin GAP-related
domain (GRD), which is encoded by exons 20–27a of
the NF1 gene and functions by down-regulating Ras acti-
vity.4,5 Two other domains of neurofibromin have been
described—a cysteine/serine–rich domain (CSRD) and a
Sec14p domain.6,7
The major clinical features of NF1 are multiple cafe´-au-
lait (CAL) spots, skinfold freckling, benign neurofibromas,
and Lisch nodules. The development of these features in
patients with NF1 is age dependent, with six or more CAL
spots usually present by the 2nd year of life, whereas cu-
taneous neurofibromas develop only later in childhood or
in adulthood. Cutaneous neurofibromas are present in al-
most all patients with NF1 by age 20 years.1,8 They lie
within the dermis or epidermis and are found to move
with the skin when it is manipulated on examination.
Neurofibromas may also develop at any point along the
course of the peripheral nerves that arise from the spinal
root outward. The neurofibromas that develop on the
more peripheral nerves are usually palpable as discrete
nodular subcutaneous swellings and are usually painful
www.ajhg.org The American Journal of Human Genetics Volume 80 January 2007 141
on palpation. These deeper lesions are usually referred to
as “subcutaneous” or “nodular” neurofibromas, and they
were reported to be present in 27% (81/298) of patients
in one study.9 Only a small proportion of these neurofi-
bromas cause symptoms sufficient to require their re-
moval; only ∼5% (4/86) of adults with NF1 in a Welsh
population study had had one removed because of local-
ized paresthesia, whereas symptomatic spinal neurofibro-
mas were removed in only 2% (2/86) of the affected in-
dividuals in the same study.1,10
The other main type of neurofibroma are those referred
to as “plexiform” neurofibromas, which can be divided
into two types—diffuse and nodular.11 Diffuse neurofibro-
mas are the most common form; they are found on rou-
tine examination of the skin and usually present as diffuse
subcutaneous swellings with ill-defined margins. They
were present in 30% of patients in the Welsh series.1 The
overlying dermis and epidermis are often affected by a
combination of hypertrophy, pigmentation, and hyper-
trichosis. Most of these lesions are located on the trunk
and are not associated with major problems. Those located
on the face, however, may be associated with major dis-
figurement, and large lesions located elsewhere may be
associated with significant bony and/or skin overgrowth.
The nodular plexiform neurofibromas may not be obvious
on routine examination because they are located more
deeply within the body, involving either the major nerve
plexuses or the spinal roots. The advent of computed to-
mography and magnetic resonance imaging scanning has
given us the opportunity to study the frequency of these
internal tumors in populations with NF1. These studies
have shown a high frequency of asymptomatic spinal and
internal plexiform lesions.12–14
Numerous other disease complications affecting various
body systems can occur, and their development usually
cannot be predicted, even within families. These include
learning problems, various malignant tumors, scoliosis,
long-bone pseudarthrosis, and cardiovascular disease in
the form of arterial stenosis and pulmonary valve
stenosis.1,15,16 There are a number of minor NF1 features
that are not usually associated with significant morbidity
but that are encountered at a much greater frequency in
patients with NF1 than in the general population. These
features include short stature, macrocephaly (both true
and relative), and pectus excavatum or carinatum.1,17
Rare families have been reported in which the majority
of affected individuals exhibit very similar NF1 features
in two or more generations. The best-defined of these fam-
ilies are those with familial CAL spots alone, with or with-
out skinfold freckling.18–20 Additional examples include
families with Watson syndrome—characterized by pul-
monary stenosis, learning problems, and paucity of cu-
taneous neurofibromas21–23—and families with multiple
spinal neurofibromas.24,25 Of these various familial sub-
types, only Watson syndrome appears to be genetically
homogeneous but exhibits allelic heterogeneity. Families
have been reported with both CAL spots and spinal neu-
rofibromas that are linked or unlinked to the NF1 gene.18–
20,24,25 In our clinical experience, such families represent
!5% of an NF1 clinical population. The majority of fam-
ilies exhibit wide intrafamilial variation in both the num-
ber of major features and the occurrence of complications.
Two studies quantitatively analyzed the familial variation
in NF126,27 and found evidence for the involvement of
modifying genes, and perhaps also the normal NF1 allele,
in the development of particular disease features.
Subsequent to the cloning of the NF1 gene in 1990,
numerous studies have looked at genotype-phenotype
correlation in NF1.28,29 However, with the exception of
those patients with the NF1 microdeletion syndrome who
develop a large number of neurofibromas for their age,
exhibit dysmorphic features, show a probable increased
predisposition to the development of malignant periph-
eral nerve–sheath tumors (MPNST), and exhibit cardiac
abnormalities and overgrowth,30–41 no other clinically sig-
nificant findings have been reported.
The finding of the same DAAT mutation in exon 17 of
the NF1 gene in three families with no neurofibromas
prompted us to review our own mutation database for
patients with the same mutation and to contact colleagues
in other laboratories worldwide. We here report a cohort
of 21 unrelated probands, along with an additional 26
affected relatives, all of whom have the same inframe AAT
deletion but no cutaneous neurofibromas.
Material and Methods
Samples from the probands of the three original large multige-
neration families (fig. 1A–1C) were referred to the DNA service
laboratory in Cardiff because of their unusual phenotypes. Having
identified the same mutation in these families, we examined the
clinical phenotypes exhibited by four other patients whom we
had previously identified with this specific genotype, and we also
contacted relevant laboratories worldwide that had extensive ex-
perience of NF1 genotyping, to ascertain other patients with this
genotype. This study was approved by the appropriate institu-
tional review board.
A clinical questionnaire was completed for each patient. The
clinical data on pulmonic stenosis were based on the clinician
declaring lack of or presence of pulmonic stenosis. The signifi-
cance of clinical findings was calculated using the Z test for pro-
portions. The one-tailed probabilities associated with the result-
ing Z values were used to estimate the significance of the
difference. Sporadic cases of NF1 who were younger than 6 years
were excluded from analysis because, at their age, they would not
be expected to have developed cutaneous neurofibromas.
NF1 mutation screening in these families involved a variety of
complementary mutation-detection techniques, including SSCP,
heteroduplex analysis, denaturing high-performance liquid chro-
matography, direct sequencing, RT-PCR, and multiplex ligation-
dependent probe amplification (MLPA).42–47
Bioinformatic Sequence Analysis: Complexity Analysis
To assess the potential contribution that the local DNA sequence
structure might have made to the molecular mechanism that
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Figure 1. Five unrelated multigeneration families with NF1, in which each clinically assessed affected individual (identified by family
numbers) has the same 3-bp AAT deletion mutation but has not developed cutaneous neurofibromas.
produced this specific NF1 microdeletion, we performed com-
plexity analysis of the immediate flanking DNA sequence.48,49
In essence, complexity analysis involves the partitioning of a
given sequence S into r consecutive fragments: Sp S(1:i )S(i 1 1
… , where each is the longest1:i ) S(i  1:i p N) S(i  1:i )2 r1 r k1 k
fragment downstream of position for which a direct, inverted,ik1
or symmetric sequence copy is located upstream of position
and where N is the length of the sequence S. For example,i  1k1
if CCACTCC, then the partition of S computed withSp ACA
respect to direct repeats is A-C-AC-CAC-T-CC. The first, second,
and fifth fragments are of length 1, since nucleotides A, C, and
T do not occur upstream of their first-occurring positions. The
third fragment (AC) is a copy of substring , the fourth frag-S(1:2)
ment (CAC) is a copy of substring , and the sixthS(2:4)p CAC
fragment (CC) is a copy of substring . The number of frag-S(4:5)
ments in the partition, , is termed “the complexity of S.”C(S)p r
Thus, for the sequence in the example given above, the com-
plexity with respect to direct repeats is 6. In a similar way, se-
quence complexity can be calculated with respect to inverted
repeats and symmetric elements.
A previous complexity analysis of ∼4,000 microdeletions and
∼2,000 microinsertions derived from the Human Gene Mutation
Database (HGMD) demonstrated that, in 80%–90% of such mu-
tations, repetitive elements identified as making the most sig-
nificant contribution to the change in sequence complexity, con-
sequent to a mutation, were of those sequence repeats that were
also directly involved in mediating the mutational change itself.
Hence, the most probable mechanism of mutation is that in
which the change in complexity is maximized.49,50
Results
The study group consisted of 21 unrelated probands and
26 affected relatives. The NF1 clinical features exhibited
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by these 47 affected individuals are summarized in table
1, and pedigrees for the five families in which at least 2
affected individuals were studied are shown in figure 1.
The ages of the 47 individuals (21 males and 26 females)
examined ranged from 2 to 65 years: 2 were younger than
5 years, 3 were aged 6–10 years, 25 were aged 11–20 years,
2 were aged 21–30 years, 7 were aged 31–40 years, and 8
were older than 40 years.
The individuals in families A–G were all examined at
the time of data collection for the study. Family E was
recently reported because of its NF1 and Noonan syn-
drome (NS) phenotypes.51 The DNA samples from the re-
maining probands had been previously genotyped in var-
ious NF1 research laboratories, and only a few of these
patients were subsequently followed up for this study. The
proband in family N was originally referred to our labo-
ratory with a diagnosis of Watson syndrome, and this in-
dividual was included in a previous study.29
All affected individuals analyzed in this study were con-
firmed as having the same NF1 mutation: a 3-bp deletion
in exon 17 (c.2970-2972delAAT).6,42,44,52–54 The mutation is
predicted to lead to the loss of one of a pair of methionine
residues, 991 and 992, of the neurofibromin protein. This
mutation was not found in any of the eight clinically as-
sessed unaffected relatives analyzed from families A–C.
Any possibility that this 3-bp deletion represents a poly-
morphism was excluded, since this mutation completely
segregated with the disease in 29 affected individuals from
the five unrelated multigeneration families. Additionally,
in two sporadic cases of NF1 with this mutation (from
families H and T), no such sequence change was found in
either set of the unaffected parents. This sequence alter-
ation was not detected in 1900 normal chromosomes 17
analyzed. Finally, this 3-bp deletion was the only sequence
change identified in five unrelated patients with NF1 for
whom comprehensive NF1 mutation analysis was con-
ducted; this included the direct sequencing of the entire
coding region, as well as analysis to detect the presence
of either a total gene deletion or a multiexon deletion/
duplication by MLPA.47
In table 2, the frequencies of NF1 features in this cohort
are compared with those found in previous large NF1
studies.1,9,10,17,55 The common clinical features in all af-
fected individuals in this cohort are six or more CAL spots,
with 30 of 47 individuals having associated skinfold freck-
ling. None of the individuals examined had cutaneous
neurofibromas, and no clinically obvious plexiform le-
sions were reported. One patient in family T had had a
symptomatic spinal neurofibroma removed. In family D,
only one branch of the family was available for exami-
nation by the clinical geneticist, and none of these af-
fected subjects had any neurofibromas. Cutaneous neu-
rofibromas were, however, reported to be present in the
remaining affected adults in this family, but this could not
be formally assessed, nor could the mutation be analyzed
in this branch of the family.
In table 2, we present comparisons of the different kinds
of neurofibromas in this study with those in previous large
studies and provide statistical analysis of the data. For cu-
taneous neurofibromas, we looked at the frequency in
those aged 20 years, since the majority of patients with
NF1 in previous studies have had these lesions by that
age. We did not analyze subcutaneous lesions because
these could be missed on routine examination. For plex-
iform lesions, we only analyzed the frequency of lesions
that would be clinically obvious, as some smaller lesions
may be missed on casual examination. We therefore an-
alyzed these lesions only in patients aged 10 years and
compared their frequency with that of the major plexi-
form neurofibromas found in a previous study (in which
they were defined as “large head and neck lesions” and
“limb/trunk lesions associated with significant skin/bone
hypertrophy”).1,10
With regard to the occurrence of NF1 complications, it
is often difficult to make definite conclusions, since the
frequency of the majority of them is !5% in large NF1
cohorts. However, the data suggest a significantly lower
frequency (at a 5% level [8/47]) of learning problems (table
2), although it was not always possible to use the rigorous
criteria often used for defining “learning disability.” Sco-
liosis occurred at a frequency similar to that in previous
studies. Pulmonary stenosis, however, occurred in appar-
ent excess, but with three of the four cases in one family.
The minor disease features were present at a frequency
much lower than normal, with only 4 of 45 having mac-
rocephaly (i.e., head circumference at or above the 97th
percentile), 5 of 47 having short stature (i.e., height at or
below the 3rd percentile), and 7 of 45 having a pectus
abnormality.
Of the other medical problems, vascular disease pre-
senting as arterial stenosis is a rare but definite NF1 com-
plication (e.g., individual B2 in table 1). Two probands
had additional medical problems that we felt were coin-
cidental—a cerebellar cavernous hemangioma in the pro-
band of family C (individual C6) and posterior urethral
valves in the patient with sporadic NF1 in family M.
Sequence Analysis
The maximum change in complexity was observed on the
measure with respect to inverted repeats; therefore, it was
hypothesized that the molecular mechanism most likely
to have produced this particular mutation is the process
of quasi-palindrome correction. Examination of the par-
tition of the nucleotide sequences flanking this deletion
identified two almost-perfect inverted repeats, TAGCA-
TTG and CaatGATGTTA (deleted nucleotides are un-
derlined, and perfect Watson-Crick base-pairing nucleo-
tides are shown in bold). These two inverted repeats could
have mediated the hairpin-loop structure formation (fig.
2). In addition, G-T pairing might also have contributed
to stabilizing the hairpin-loop, since the overall shape of
G-T pairing is similar to the Watson-Crick pairing.56 It is
the deletion of the aat sequence, which bulges out of the
hairpin-loop structure, that is predicted to lead to a quasi-
144 The American Journal of Human Genetics Volume 80 January 2007 www.ajhg.org
Table 1. Clinical Details for 47 Affected Individuals from 21 Families with NF1 with c.2970-2972 delAAT
Family
and
Individual
Sex/
Age
(years)
Clinical Feature
Axillary/
Inguinal
Freckling
Lisch
Nodules
Short
Stature Macrocephaly
Pectus
Abnormality Scoliosis
Pulmonary
Stenosis LDa Other
A:
1 F/59 Y Y N N N N N N N
2 M/65 N N N N N N N N Multiple
lipomas
3 F/56 Y N N N N N N N N
4 F/35 Y N N N N N N N Multiple
lipomas
5 M/36 Y N N Y N N N N N
6 M/5 Y N Y N N N N Y N
7 M/2 Y Y N N N N N N N
B:
1 M/50 Y N N Y N N N N N
2 F/14 Y N N N Y Y N Y Arterial
stenosis
3 F/15 Y N N N Y Y N N N
C:
1 F/63 Y N N ? N N N N N
2 F/41 Y N N N N N N N N
3 F/40 Y N N N N N N N N
4 M/17 Y N N N N N N N N
5 F/16 Y N N N N N N N N
6 F/8 Y N N N N N N Y Cerebellar
cavernous
hemangioma
7 F/16 Y N N N N N N N N
8 F/14 Y N N N N N N N N
9 F/13 Y N N N N N N N N
10 F/8 Y N N N N N N N N
D:
1 F/38 N N N N N N N N N
2 F/11 N N N N N N N N N
3 F/11 N N N N N N N N N
4 M/17 N N N N N N N N N
E:
1 F/36 Y ? N N N N N N N
2 F/14 N ? Y N Y N N N N
3 M/13 Y ? Y N Y N Y Y N
4 M/10 N ? N N Y N Y Y N
5 F/8 N ? Y N Y N Y N N
F:
1 M/53 N ? N N N N N N N
2 M/19 Y Y N N N N N Y Atrial septal
defect
G:
1 M/51 Y N N ? ? N N N N
2 M/20 Y N N ? ? N N N N
H:
1b M/15 N N N N N N N N N
I:
1 M/34 N N N N N Y N N N
J:
1b F/18 Y N N Y N N N N N
K:
1 F/8 Y N N N N N N N N
L:
1 M/12 Y N N N N N N N N
M:
1b M/11 N N Y N N N N Y Genitourinary
abnormalities
N:
1 F/12 N ? N N Y N Y N N
(continued)
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Table 1. (continued)
Family
and
Individual
Sex/
Age
(years)
Clinical Feature
Axillary/
Inguinal
Freckling
Lisch
Nodules
Short
Stature Macrocephaly
Pectus
Abnormality Scoliosis
Pulmonary
Stenosis LDa Other
O:
1 M/17 Y ? N Y N N N Y N
P:
1b M/15 Y N N N N N N N N
Q:
1b M/13 N N N N N N N N N
R:
1 M/36 N N N N N N N N N
S:
1 F/10 Y N N N N N N N N
T:
1b F/27 Y ? N N N Y N Y Spinal
neurofibroma
U:
1b F/25 Y N N N N N N N N
NOTE.—All individuals had no cutaneous, subcutaneous, or clinically obvious plexiform neurofibromas. All had six or more CAL macules, except
for patient A3.
a LD p learning difficulty.
b Sporadic cases of NF1. All other individuals were familial cases.
palindrome correction and to the stabilization of the hair-
pin loop.
Possible Effect of c.2970-2972delAAT on RNA Splicing
cDNA-based mutation analysis in blood lymphocytes
showed normal splicing of exon 17, hence refuting the
hypothesis that this 3-bp deletion might exert its patho-
genicity by causing splicing abnormalities43,53; this was the
only mutation identified. Analysis of normal and mutant
DNA sequence was undertaken using both splice-site pre-
diction software57,58 and exon splice-enhancer software
(ESE-Finder).59 In agreement with cDNA work, neither of
the splice-site tools predicted any change in the identified
splice site resulting from this mutation. Analysis of the
mutant sequence with the ESE-Finder program, however,
demonstrated that two new potential Ser-Arg–rich protein
binding sites were created by the 3-bp deletion.
Discussion
We present data demonstrating that a 3-bp AAT mutation
in exon 17 of the NF1 gene is associated with a very mild
NF1 phenotype in the majority of cases. The most striking
finding is the paucity of cutaneous, subcutaneous, and
superficial plexiform neurofibromas in these patients. Cu-
taneous neurofibromas, being one of the hallmark clinical
features of NF1, are present in almost all adult patients
with NF1, in whom they often represent a major cause of
morbidity. These data not only have immediate clinical
application but, in a longer term, may also provide a better
understanding of the biological reasons why patients with
NF1 with the specific c.2970-2972delAAT mutation do not
develop this kind of neurofibroma.
The 3-bp inframe deletion is predicted to produce a neu-
rofibromin protein that lacks only a single methionine
residue. The amino acid sequence surrounding this de-
leted methionine is highly conserved, and this sequence
would therefore be expected to have a crucial functional
role in the protein. Interestingly, this region of neurofi-
bromin has been identified as a CSRD of the protein,60 a
domain that contains a number of potential cyclic aden-
osine monophosphate (cAMP)–dependent protein kinase
A binding sites, indicating a possible role in cAMP sig-
naling.61 However, no suitable functional assay with
which to monitor the overall activity of this CSRD domain
is currently available. Indeed, the only confirmed bio-
chemical test applicable to monitoring of neurofibromin
activity involves the assay that measures the intrinsic ac-
tivity of the GRD.36,62,63 The increased activation of Ras
that is observed in neurofibromin-deficient cells often
manifests itself by the increased activation of several
downstream Ras effectors, including RAF, ERK1/2, PI3K,
and p21-activation kinase. The activation of these various
signaling pathways is likely to contribute to the increased
proliferation observed in Nf1/ Schwann cells and as-
trocytes, as well as to the increased proliferation and mo-
tility of the heterozygous Nf1/ mast cells present in
neurofibromas.63
Determination of the consequences of the methionine
deletion on the overall physical structure of the mutant
protein might reveal some information on the potential
function of this region of neurofibromin.64 The lack of a
suitable soluble polypeptide for this region of the protein
does, however, preclude any immediate study of the pos-
sible effects of this mutation on the protein’s three-dimen-
sional structure (K. Scheffzeck, personal communication).
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Figure 2. An AAT microdeletion within exon 17 of the NF1 gene
mediated by palindrome correction and the formation of a more
prominent hairpin-loop structure.
Table 2. NF1 Clinical Features in 47 Individuals with the 3-bp AAT Deletion
Compared with Clinical Data Derived from Previous Large-Scale Patient-Cohort
NF1 Studies
NF1 Feature
Frequency
P
Present Patient
Cohort
Previous Patient
Cohorts1,9,10,14,55
Cutaneous neurofibromasa 0/18 99/991 .0000
Major external plexiform neurofibromasb 0/41 7/1151 .0000
Axillary freckling 30/47 95/1341 .1835
Macrocephaly 4/45 39/1151 .0007
Short stature 5/47 39/1241 .0027
Pectus anomalies 7/45 36/12714 .0443
Learning problems 8/47 41/1241 .0192
Scoliosisc 2/20 11/961 .4254
Pulmonary stenosis 4/47 25/2,33255 !.0001
Symptomatic spinal neurofibroma 1/47 2/961 .4932
a In patients aged 20 years.
b In patients aged 10 years.
c In patients aged 18 years.
It is possible that the mutant neurofibromin functions
as a hypomorphic allele, in which the loss of the single
methionine at either 991 or 992 results in a reduction in
the overall level of neurofibromin in cells, but not to such
an extent that it results in the development of neurofi-
bromas. Assessment of the effect of this mutation at the
protein level is, therefore, required. RT-PCR–based muta-
tion analysis of mRNA from several patients with the
DAAT mutation appears to indicate that this mutation is
unlikely to have any effect on the overall splicing of the
NF1 transcript, since sequencing of the mutant mRNA
demonstrated that the mutant transcript lacked only one
of the two AUG trinucleotides at codons 991 and 992.53
It is not known, however, whether the shortened mRNA
is translated into a correspondingly shortened neurofi-
bromin. Since this mutation is located on the border of
the CSRD domain of neurofibromin, it is possible that the
loss of methionine within this region may induce the ab-
errant phosphorylation of the threonine residue located
immediately adjacent to the deleted methionine. It is im-
portant to ascertain whether this mutant neurofibromin
exhibits aberrant interactions with other proteins. In an
attempt to address some of these questions, we propose
to undertake microarray analyses to assess changes in both
gene expression and genomic copy-number variation, to
identify potential modifying loci.
A total of 1,255 inframe deletions, ranging in size from
3 to 21 bp, are identified in the HGMD. Whereas the vast
majority of these mutations are predicted to have arisen
via a slipped-mispairing process,65 ∼3% of these mutations
exhibit evidence for definite palindrome correction as the
mechanism likely to underlie such inframe deletions.66
Notably, this DAAT mutation in exon 17 is predicted to
be the result of a deletion of an aat sequence that looped
out of a predicted hairpin structure, producing a palin-
drome sequence correction and leading to the increased
stabilization of the hairpin loop.
Neurofibromas are heterogeneous at the cellular level,
being composed of Schwann cells—along with fibroblasts,
mast cells, and perineurial cells—and it is only the
Schwann cells that carry somatic mutations.67,68 In a mu-
rine Nf1 model system, it has been shown that it is the
interaction of haploinsufficient mast cells with Schwann
cells, which are completely deficient of neurofibromin,
that induces the development of neurofibromas.69 It is,
therefore, possible that, in patients with the DAAT mu-
tation, this cellular interaction between mast cells and
Schwann cells is disrupted, resulting in the absence of
neurofibroma formation.
Before this report, there has been no confirmed corre-
lation, to our knowledge, between a specific small NF1
gene mutation and the NF1 phenotype. We reported a
possible association between missense mutations and a
lower frequency of Lisch nodules, but this finding needs
confirmation in a larger cohort.29 Until now, the only con-
sistent genotype-phenotype correlation has been in those
patients with an NF1 microdeletion. These patients have
specific dysmorphic features, a heavy burden of cutaneous
neurofibromas, and, most likely, an elevated risk of
MPNST.30,38,39,70 It has been suggested that the codeletion
of the NF1 gene, along with some as-yet-unknown mod-
ifying gene(s), may jointly function in potentiating neu-
rofibromagenesis. This may occur, either by the increase
in the frequency of NF1 somatic mutations or by the se-
lection for increased growth of neurofibromin-deficient
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Schwann cells.71 Our data now indicate that specific in-
tragenic mutations may also be associated with the ex-
pression of specific clinical features.
High levels of intra- and interfamilial clinical variability
are observed in many patients with NF1, even those with
identical NF1 mutations.16,72 Attempts at making geno-
type-phenotype correlations in NF1 are likely to be con-
founded by the strong effect of age on a patient’s phe-
notype73 and the lack of independence of many of these
clinical features.27,74 Furthermore, the great variety of path-
ogenic NF1 mutations scattered all over the gene,6,42–44,46
combined with the challenges to correctly classify the mu-
tations according to their expected effect on protein func-
tion, greatly hampers these studies.75,76
In the present study, we were alerted to the significance
of the DAAT mutation because of the absence of clinically
detectable neurofibromas in affected individuals in the
initial three families. In the Welsh population study, cu-
taneous neurofibromas were present in all affected indi-
viduals older than 20 years,1 yet none of the adults in this
study had any lesions. In one of the families (fig. 1D), one
branch of the family was unavailable for study but was
reported to have neurofibromas. Modifying genes could
be a possible explanation. An alternative would be that
this family has more than one NF1 mutation.77 Indeed,
we have identified three separate NF1 mutations in the
affected members of a Portuguese family,78 and a further
three families, each with two different NF1 mutations,
have recently been found (M. Upadhyaya and L. Messiaen,
unpublished data). With regard to other kinds of neuro-
fibromas, we must be more cautious, since subcutaneous
neurofibromas and small superficial plexiform lesions
could be missed on routine examination. However, the
data presented suggest that the DAAT mutation is also
associated with a major decrease in the frequency of these
lesions. This is important clinically, because these lesions
have been shown to be associated with an increased risk
of MPNST.38 We cannot comment on asymptomatic in-
ternal neurofibromas, since no body or spinal imaging has
been undertaken. One patient (in family T) had a symp-
tomatic spinal lesion removed, which indicates that such
lesions may also occur with this mutation.
The absence of any form of neurofibroma has previously
been observed in families with familial CAL spots alone
and also in individuals with Watson syndrome, who gen-
erally have few, if any, cutaneous neurofibromas. In the
absence of specific associated mutations, these diagnoses
can be made only in multigenerational families. Of the
reported families with CAL spots alone, only one has been
linked to the NF1 locus.20 The affected family members
each had six or more CAL spots only and no other NF1
features, although minor disease features are not specifi-
cally reported.
The majority of individuals in our cohort had associated
skinfold freckling, which was not a feature in the family
reported elsewhere.20 However, there is a possibility that
the DAAT mutation may be the causative mutation in fam-
ilies linked to chromosome 17.20 Three probands (of fam-
ilies H, M, and Q) in the present study do not fulfill the
diagnostic criteria for NF1, since they have sporadic cases
with CAL spots only. That each of these individuals ex-
hibits the same 3-bp AAT deletion—already shown to
completely segregate with the disease in five large unre-
lated families with NF1—and in the absence of any other
detected NF1 mutation, suggests that this deletion is also
highly likely to be the disease-causing mutation in these
three individuals. We therefore suggest that this 3-bp de-
letion may be the causative mutation in the families with
rare chromosome 17–linked autosomal dominant CAL.
We therefore suggest that patients who present only with
CAL spots should initially be tested for the DAAT
mutation.
Molecular studies of Watson syndrome21–23 have shown
it to be linked to the NF1 locus; however, several different
mutations have been found, including an 80-kb deletion22
and an inframe tandem duplication in exon 28.23 Of the
present cohort, the proband in family N was also exam-
ined as part of that previous study21 and was thought to
exhibit a phenotype similar to those of families with a
Watson-like syndrome in which 17q11.2 linkage was dem-
onstrated. The identification of another different muta-
tion in a patient with Watson syndrome in the present
study would suggest that the NF1 mutation alone is un-
likely to be the sole cause of the observed phenotype.
Three affected individuals (from family E) all presented
with pulmonary valve stenosis, and this family was re-
ported elsewhere, since they exhibit several other NS fea-
tures. It has been suggested that NF1-NS (NFNS), as char-
acterized by the overlapping features of NF1 and NS, exists
as a separate entity still needs to be ascertained, but, with
current evidence, this now seems unlikely.79,80 Molecular
studies of cohorts of individuals with NFNS have identified
a variety of NF1 mutations, several of which were also
found in patients with NF1 who did not exhibit any ob-
vious NS-like features.54,81 NFNS features were reported
only in the individuals in family E in the present study,
although the DAAT mutation was previously found in one
of the affected individuals in an NFNS study.81 This sug-
gests that, although the AAT-deletion mutation alone may
be insufficient to produce the NFNS phenotype, this mu-
tation may still confer an increased predisposition to this
phenotype. Given the recent findings of mutations in
other components of the Ras–mitogen-activated protein
kinase pathway in several syndromes with features that
overlap with NF1 and NS, one possibility to explain the
variable NFNS phenotype in people with NF1 gene mu-
tations is the interaction with functional polymorphisms
in other genes in the pathway.82
The clinical data from our cohort (tables 1 and 2) show
a significant reduction of many NF1 features. Quantitative
studies of families with NF1 have suggested that the de-
velopment of the disease features is significantly associ-
ated with unlinked modifying genes, and these may be
different for each disease feature.26 Szudek et al.27 sug-
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gested that the normal NF1 allele may also play a role.
Our data give support to the role of other factors, since
the phenotype varies even in this cohort. Pulmonary ste-
nosis is the only NF1 complication that appeared in excess
in our study; since it is also a feature in the patients with
Watson syndrome, there may be a link between the pau-
city of neurofibromas and a predisposition to pulmonary
stenosis.
It is the physical structure of a disease-associated pro-
tein, in conjunction with its interactions with other pro-
teins, that is usually considered to be responsible for or
to contribute to the observed variation in the clinical phe-
notype of a particular disorder. Therefore, to better inter-
pret any potential genotype-phenotype relationships, one
needs to consider the combinatorial effects of multiple
different mutations and polymorphisms, whether allelic
or not. A number of good examples are now known, in
which different sequence variants, even within the same
gene, may exert quite different effects on both the struc-
ture and function of the encoded protein and, hence, re-
sult in the observed interindividual variation in the clin-
ical phenotype, or, indeed, in which different mutation
types of a gene may result in completely different clinical
phenotypes. For example, mutations of the lamin A/C
gene (LMNA) are known to be associated with at least 12
different inherited disorders. These include a variety of
muscular dystrophies, several variant lipodystrophies, and
at least two progeria-like aging syndromes. However, close
examination of the spectrum of LMNA mutations found
in individuals affected with these various disorders has
failed to find any direct association between the observed
clinical phenotype and either the mutation type or its
location within the gene.83,84
Three additional unrelated patients have been described
with this specific mutation, but the required clinical de-
tails are not currently available.6,81 Fahsold and colleagues,
in their large mutation study,6 identified two unrelated
patients with NF1 with the DAAT mutation but, in addi-
tion, found another patient with NF1 who had a different
3-bp inframe deletion that resulted in the loss of an ATG
in exon 21 of the NF1 gene. Interestingly, this mutation
was also found to delete one of a pair of methionine res-
idues (codons 1214 and 1215) from the mutant neurofi-
bromin; however, no detailed clinical information is avail-
able for this patient.
In conclusion, the present study provides the first con-
firmed molecular evidence implicating the role of a spe-
cific 3-bp inframe deletion of the NF1 gene in the deter-
mination of a particular clinical phenotype—namely, the
almost complete lack of the development of cutaneous,
subcutaneous, and superficial plexiform neurofibromas.
This compelling evidence for a defined genotype-pheno-
type correlation should prove invaluable in diagnosis and
genetics counseling for future patients with NF1.
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